# Brigimadlin

Source: https://onco.cc/drugs/brigimadlin/  
OnCo record `brigimadlin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Brigimadlin is a tablet that frees the p53 'guardian' protein from MDM2, the protein that liposarcomas make in excess to keep p53 switched off. It is being compared with doxorubicin as first treatment for dedifferentiated liposarcoma in a phase 2/3 trial.

## Summary

Brigimadlin (BI 907828) is Boehringer Ingelheim's oral MDM2-p53 antagonist, dosed once every three weeks to limit the thrombocytopenia that troubled earlier MDM2 inhibitors. Dedifferentiated liposarcoma almost always carries MDM2 amplification with wild-type TP53, so it is the model disease for the class. In the phase 1a/1b trial, responses and long disease control were seen in MDM2-amplified liposarcoma.

The Brightline-1 phase 2/3 trial compares brigimadlin with doxorubicin as first-line treatment for advanced dedifferentiated liposarcoma, and Brightline-2 tests it in other MDM2-amplified, TP53 wild-type cancers such as biliary tract and pancreatic cancer. The liposarcoma page names it with CDK4/6 inhibitors among the targeted drugs in late trials for MDM2-amplified disease.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-17
- Also known as: BI 907828; BI-907828
- Tags: subtype-drugs-wave
- Code: BI 907828
- Modality: Oral MDM2-p53 antagonist
- Mechanism: Binds MDM2 in the pocket that normally holds p53, releasing p53 from degradation; in tumours with MDM2 amplification and intact TP53, such as dedifferentiated liposarcoma, restored p53 stops the cycle and triggers cell death.

## Connected records

- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/)
- cancers: [Liposarcoma](https://onco.cc/cancers/liposarcoma/)
- targets: [MDM2](https://onco.cc/targets/mdm2/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/brigimadlin.json